To validate these findings, we examined tumor tissues from patients with embryonal tumor with multilayered rosettes (ETMR) (n = 10), group 3 MB (n = 5), group 4 MB (n = 5), Sonic hedgehog (SHH) MB (n = 9), and high-grade glioma (n = 6), and evaluated the intensity and pattern of GPC2 immunoreactivity compared to neuroblastoma used as positive control (Figure 1B; Figure S2). This evidence concerns the gene GPC2 and central nervous system cancer.